Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants
Antimicrobial Agents and Chemotherapy · 02.09.2026 · 70 (9)
DOI: 10.1128/aac.01930-25 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.09.2026. Verfasst von Jerry Nedelman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Global Alliance for TB Drug Development, New York, New York, USA. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Agency for International Development, Innovative Health Initiative, Foreign, Commonwealth and Development Office.
Abstract (Originalsprache)
TBAJ-587 is a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile than the first-generation bedaquiline. It is currently under development for the treatment of drug-susceptible and drug-resistant tuberculosis. A first-in-human trial of TBAJ-587, including single and multiple ascending oral doses and a dedicated food-effect cohort, was conducted in 92 healthy adults. Plasma exposures of TBAJ-587 were generally linear for AUC tau and slightly subproportional for C max , with the major circulating active metabolite, M3, remaining low relative to the parent. A high-fat meal increased the mean C max and AUC last 3.46- and 2.26-fold, respectively. TBAJ-587 accumulated with multiple dosing over the 28-day period, with mean accumulation ratios across the three tested doses ranging from 1.69 to 2.32 for C max and from 2.74 to 3.73 for AUC tau . However, steady-state conditions were not yet reached on day 28. Mean terminal half-lives after 28-day dosing of TBAJ-587 ranged from approximately 80 to 111 days. There were no deaths or serious adverse events, and TBAJ-587 was generally safe and well tolerated at single doses of 25–800 mg under fasting conditions and multiple doses of 50–200 mg once daily for 28 days after a standard breakfast. In addition, no dose- or time-dependent effects were noted for any of the other safety and tolerability parameters, including no clinically significant effects on the QTc interval. These results support further investigation of TBAJ-587 for the treatment of tuberculosis. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04890535 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Alliance for TB Drug Development, New York, New York, USA.
- QPS Netherlands BV, Groningen, the Netherlands.
- Vast Therapeutics, Morrisville, North Carolina, USA.
- IdiPAZ, University Hospital La Paz, Servicio Madrileño de Salud (SERMAS), Madrid, Spain.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center, Groningen, the Netherlands.
ORCID-Profile: Jerry Nedelman, Antonio Lombardi, Dean Hickman, Zuzana Diamant, Maria Beumont, Eugene Sun
Förderung
- United States Agency for International Development
- Innovative Health Initiative
- Foreign, Commonwealth and Development Office
- Bill and Melinda Gates Foundation
- University of Dundee
- Irish Aid
- European Federation of Pharmaceutical Industries and Associations
- Gates Family Foundation
Zitieren
APA
Nedelman, J., Conradie, A., Lombardi, A., Hickman, D., Abd-Elaziz, K., Dogterom, P., Bruinenberg, P., Sansuán, A. J. C., Sakiman, E., Diamant, Z., van Duinen, J., Beumont, M., & Sun, E. (2026). Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants. Antimicrobial Agents and Chemotherapy, 70(9). https://doi.org/10.1128/aac.01930-25
Vancouver
Nedelman J, Conradie A, Lombardi A, Hickman D, Abd-Elaziz K, Dogterom P, et al. Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants. Antimicrobial Agents and Chemotherapy. 2026;70(9). doi:10.1128/aac.01930-25
BibTeX
@article{Nedelman2026,
author = {Nedelman, Jerry and Conradie, Almari and Lombardi, Antonio and Hickman, Dean and Abd-Elaziz, Khalid and Dogterom, Peter and Bruinenberg, Paul and Sansuán, Antonio J Carcas and Sakiman, Elly and Diamant, Zuzana and van Duinen, Jolanda and Beumont, Maria and Sun, Eugene},
title = {Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {9},
doi = {10.1128/aac.01930-25}
}
EUVIMED